More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 2

Co-Diagnostics completed clinical and analytical studies for its PCR Flu A/B & RSV test and plan

Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in hono

Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnosti

Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regio

 Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnost

Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD

Co-Diagnostics shares jump 28% following a $3.0M private placement and key progress on its Bundibugy

https://www.cdc.gov/ebola/situation-summary/index.html

he lease execution represents a key milestone as CoMira advances domestic manufacturing capabilities

Facility in Sudair Industrial City is expected to position CoMira among the early domestic manufactu

Co-Diagnostics (OTC:CODX) reported quarterly losses of $(16.65) per share. This is a 53.88 percent d

U.S. stocks traded lower, with Dow falling over 100 points. Energy shares climbed 1%, while consumer

Dow falls 100+ points, S&P 500 and NASDAQ also down. Energy sector sees gains, consumer discreti

Co-Diagnostics (CODX) stock falls over 50% as they announced a $7 million offering and Saudi joint v